All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Copenhagen University reverses admissions rule after criticism

By

Juni Westmark

2d agoen

Source

NordiskPostCopenhagen University reverses admissions rule after criticismnordiskpost.com
Snippet from the RSS feed
Copenhagen University admissions rules have been changed again after criticism from students and Denmark’s higher education authorities, allowing applicants who must take a sickness exam in August to be considered for a study place this year. The University of Copenhagen (Københavns Universitet, KU) confirmed the reversal shortly before the quota 1 (kvote 1) application deadline on Sunday 5 July at 12:00. The decision affects applicants who were ill during their final upper-secondary exams and will only receive their final exam certificate after the ordinary deadline. Copenhagen University admissions rule is reversed KU had recently changed its practice so that applicants who did not have their final exam certificate by 5 July at 12:00 could not be considered for admission this year. That included students who had documented illness during their final exams and therefore had to take a sickness exam (sygeeksamen) in August. The university has now reversed that line for this year’s intake. KU says applicants who must take a sickness exam can still apply, provided they submit the required documentation and upload their full exam certificate no later than 31 August. The change means that affected applicants can again be considered for a place through quota 1, Denmark’s … The post Copenhagen University reverses admissions rule after criticism appeared first on NordiskPost .

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.